How to buy Karyopharm Therapeutics stock

Karyopharm Therapeutics Inc is a biotechnology business based in the US. Karyopharm Therapeutics shares (KPTI) are listed on the NASDAQ and all prices are listed in US Dollars. Karyopharm Therapeutics employs 432 staff and has a trailing 12-month revenue of around USD$108.1 million.

How to buy shares in Karyopharm Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Karyopharm Therapeutics. Find the stock by name or ticker symbol: KPTI. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Karyopharm Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Karyopharm Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Karyopharm Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced investors

Webull

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active investors. We picked Webull for this category because its platform offers features that cater to advancing investors as well as beginners. The desktop app is outfitted with an extensive set of research tools, the mobile app gets high grades from users and traders can test strategies with a paper-trading feature.

What's in this guide?

1. KPTI shares summary
2. Compare share dealing platforms
3. Is KPTI stock a buy or sell?
4. Stock performance over time
5. Can I short KPTI shares?
6. Karyopharm Therapeutics's financials
7. How volatile are KPTI shares?
8. Does Karyopharm Therapeutics pay a dividend?
9. Other common questions

Karyopharm Therapeutics share price

Use our graph to track the performance of KPTI stocks over time.

Karyopharm Therapeutics shares at a glance

• Key figures

Information last updated 2021-03-03.

52-week range	USD$13.17 - USD$28.04
50-day moving average	USD$15.0999
200-day moving average	USD$15.3442
Wall St. target price	USD$30
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.55

Buy Karyopharm Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Webull		$0	Stocks, Options, ETFs	$0	0%	Get two free stock valued between $2.50 and $250 Open an account	Margin financing rates start at 3.99%. No monthly subscription fees for margin.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Karyopharm Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Karyopharm Therapeutics Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting Karyopharm Therapeutics shares

There are currently 15.7 million Karyopharm Therapeutics shares held short by investors – that's known as Karyopharm Therapeutics's "short interest". This figure is 10.9% up from 14.2 million last month.

There are a few different ways that this level of interest in shorting Karyopharm Therapeutics shares can be evaluated.

Karyopharm Therapeutics's "short interest ratio" (SIR)

Karyopharm Therapeutics's "short interest ratio" (SIR) is the quantity of Karyopharm Therapeutics shares currently shorted divided by the average quantity of Karyopharm Therapeutics shares traded daily (recently around 3.3 million). Karyopharm Therapeutics's SIR currently stands at 4.74. In other words for every 100,000 Karyopharm Therapeutics shares traded daily on the market, roughly 4740 shares are currently held short.

However Karyopharm Therapeutics's short interest can also be evaluated against the total number of Karyopharm Therapeutics shares, or, against the total number of tradable Karyopharm Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Karyopharm Therapeutics's short interest could be expressed as 0.21% of the outstanding shares (for every 100,000 Karyopharm Therapeutics shares in existence, roughly 210 shares are currently held short) or 0.2241% of the tradable shares (for every 100,000 tradable Karyopharm Therapeutics shares, roughly 224 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Karyopharm Therapeutics.

Find out more about how you can short Karyopharm Therapeutics stock.

Karyopharm Therapeutics share price volatility

Over the last 12 months, Karyopharm Therapeutics's shares have ranged in value from as little as $13.17 up to $28.04. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Karyopharm Therapeutics's is 0.6307. This would suggest that Karyopharm Therapeutics's shares are less volatile than average (for this exchange).

Karyopharm Therapeutics overview

Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma. The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of ow-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 2/3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration with PROMETRIKA, LLC to conduct the first randomized clinical trial for low-dose selinexor (XPOVIOÂ), an XPO1 inhibitor for hospitalized patients with COVID-19; and a cooperative research and development agreement with the National Cancer Institute for cancer therapy evaluation program. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

Frequently asked questions

• What percentage of Karyopharm Therapeutics is owned by insiders or institutions?

  Currently 9.598% of Karyopharm Therapeutics shares are held by insiders and 93.494% by institutions.

• How many people work for Karyopharm Therapeutics?

  Latest data suggests 432 work at Karyopharm Therapeutics.

• When does the fiscal year end for Karyopharm Therapeutics?

  Karyopharm Therapeutics's fiscal year ends in December.

• Where is Karyopharm Therapeutics based?

  Karyopharm Therapeutics's address is: 85 Wells Avenue, Newton, MA, United States, 02459

• What is Karyopharm Therapeutics's ISIN number?

  Karyopharm Therapeutics's international securities identification number is: US48576U1060

• What is Karyopharm Therapeutics's CUSIP number?

  Karyopharm Therapeutics's Committee on Uniform Securities Identification Procedures number is: 48576U106